Leming Shi, PhD, is a Professor at Fudan University and the Director of the International Human Phenome Institutes (Shanghai). A world-renowned leader in establishing quality standards for multiomics data, Dr. Shi's work enhances drug discovery and precision medicine. He spearheaded the international MAQC/SEQC consortia and the MAQC Society, pioneered the first suites of certified multiomics reference materials (the Chinese Quartet), and co-founded Chipscreen Biosciences (688321.SH), resulting in two novel marketed drugs (Chidamide and Chiglitazar). His research in multiomics-based precision medicine for breast cancer has significantly improved patient survival. With over 200 highly cited publications, his work has directly shaped FDA guidance and international standards on multiomics. Dr. Shi holds a PhD in computational chemistry and conducted postdoctoral research at the NIH/NCI, which launched a distinguished career spanning academic, industrial, and regulatory settings.